5 Key Takeaways

• 1

  Dry eye disease (DED) affects millions globally and can lead to significant pain and health issues, necessitating effective treatment options.

• 2

  The TFOS DEWS III guidelines recommend a personalized treatment approach for DED, potentially elevating autologous serum tears (AST) to first-line therapy.

• 3

  AST contains growth factors and nutrients similar to natural tears, promoting ocular surface healing and offering advantages over artificial lubricants.

• 4

  Vital Tears centralizes AST production, improving accessibility and consistency, with a typical delivery time of 48 hours after blood collection.

• 5

  Clinical trials show AST significantly improves DED symptoms and is gaining recognition from insurers, aiming to reduce patient costs and increase adoption.